Peter Attia· MD
The state of evidence for alleged geroprotective effects of GLP-1 receptor agonists, SGLT2 inhibitors, methylene blue, and telomere-lengthening supplements
Loading…
The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
The state of evidence for alleged geroprotective effects of GLP-1 receptor agonists, SGLT2 inhibitors, methylene blue, and telomere-lengthening supplements
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
The state of evidence for alleged geroprotective effects of GLP-1 receptor agonists, SGLT2 inhibitors, methylene blue, and telomere-lengthening supplements
In today's episode we are going to look at some geroprotective drugs like uh GLP1s things like ompic sgt2 inhibitors both of which we talked about before.